- Home
- ELAB vs NUWE Comparison
ELAB vs NUWE Comparison
Compare ELAB & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- NUWE
- Stock Information
- Founded
- ELAB 2020
- NUWE 1999
- Country
- ELAB United States
- NUWE United States
- Employees
- ELAB N/A
- NUWE N/A
- Industry
- ELAB
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ELAB
- NUWE Health Care
- Exchange
- ELAB Nasdaq
- NUWE Nasdaq
- Market Cap
- ELAB 3.2M
- NUWE 2.9M
- IPO Year
- ELAB 2023
- NUWE N/A
- Fundamental
- Price
- ELAB $5.87
- NUWE $2.71
- Analyst Decision
- ELAB
- NUWE
- Analyst Count
- ELAB 0
- NUWE 0
- Target Price
- ELAB N/A
- NUWE N/A
- AVG Volume (30 Days)
- ELAB 117.1K
- NUWE 124.9K
- Earning Date
- ELAB 11-14-2025
- NUWE 11-12-2025
- Dividend Yield
- ELAB N/A
- NUWE N/A
- EPS Growth
- ELAB N/A
- NUWE N/A
- EPS
- ELAB N/A
- NUWE N/A
- Revenue
- ELAB N/A
- NUWE $8,318,000.00
- Revenue This Year
- ELAB N/A
- NUWE $6.53
- Revenue Next Year
- ELAB N/A
- NUWE $51.63
- P/E Ratio
- ELAB N/A
- NUWE N/A
- Revenue Growth
- ELAB N/A
- NUWE N/A
- 52 Week Low
- ELAB $4.29
- NUWE $2.60
- 52 Week High
- ELAB $216.63
- NUWE $107.94
- Technical
- Relative Strength Index (RSI)
- ELAB 49.59
- NUWE 38.15
- Support Level
- ELAB $5.25
- NUWE $2.60
- Resistance Level
- ELAB $6.22
- NUWE $2.93
- Average True Range (ATR)
- ELAB 0.31
- NUWE 0.27
- MACD
- ELAB -0.12
- NUWE -0.01
- Stochastic Oscillator
- ELAB 50.00
- NUWE 7.14
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.